Skip to main content

Table 1 Sample characteristics in total sample (n = 580) and in groups defined by HIV/HCV infection status (n = 541)a

From: HCV/HIV coinfection among people who inject drugs and enter opioid substitution treatment in Greece: prevalence and correlates

  Total sample
(n = 580)
Uninfectedb
(n = 111, 20.4 %)
HCV monoinfectedc
(n = 349, 64.0 %)
HCV/HIV coinfectedd
(n = 81, 14.9 %)
N (%)e N (%) N (%) N (%)
Male (vs. Female)f 463 (79.8) 95 (85.6) 272 (77.9) 67 (82.7)
Median age [Inter-quartile range] 36 [12] 35 [7] 36 [14] 33 [10]
Greek nationality (vs. Non-Greek nationality) 554 (95.5) 109 (98.2) 332 (95.1) 76 (93.8)
Lived in urban area in the last 5 years (vs. Semi-urban/rural area in the last 5 years) 444 (79.6) 84 (77.1) 264 (78.8) 71 (91.0)
Living alone or with spouse/partner without children (vs. Living with familyg) 182 (31.9) 23 (20.7) 120 (34.4) 30 (37.0)
Homeless ≥1 night in the past 12 months (vs. Never in the past 12 months) 186 (32.6) 26 (23.4) 107 (31.2) 42 (53.2)
Did not graduate high school (12th grade) (vs. Graduated high school) 360 (62.1) 61 (55.5) 215 (62.0) 59 (74.7)
Employed (vs. Unemployed/student/other and economically inactiveh) 137 (23.7) 32 (28.8) 88 (25.4) 9 (11.1)
Incarcerated at least once in lifetime (vs. Never) 382 (66.7) 55 (50.5) 241 (69.3) 57 (72.2)
Use of primary substance ≥ 4 days a week (vs. Less frequently) 466 (80.5) 93 (83.8) 272 (78.2) 71 (87.7)
Use of ≥3 substances of abusei (vs. <3 substances of abuse) 367 (63.3) 66 (59.5) 219 (62.8) 53 (65.4)
Median length of injection (years) [Inter-quartile range] 14 [12] 10 [11] 15 [12] 13 [12]
Mean times of injection per day in the past 30 days [Standard deviation] 1.9 [3.3] 1.2 [2.0] 1.6 [3.0] 3.9 [5.4]
Non-sterile syringe in last injection (vs. Sterile syringe in last injection) 45 (8.1) 5 (4.8) 25 (7.5) 10 (12.7)
Shared syringes in the past 12 months (vs. No syringe sharing in the past 12 months) 137 (25.4) 16 (15.1) 75 (23.1) 33 (44.6)
Shared other injection equipment in the past 12 months (vs. Never in the past 12 months) 237 (43.7) 42 (40.4) 131 (40.3) 44 (57.1)
Two or more sexual partners in the past 12 months (vs. <2 partners) 211 (36.6) 42 (38.9) 120 (34.5) 35 (43.2)
Sex in exchange for money etc. in the past 12 months (vs. Never in the past 12 months/non-active) 37 (6.5) 4 (3.7) 22 (6.4) 8 (10.1)
No condom use in the last intercourse (vs. Use of condom use or non-active) 246 (43.5) 51 (47.7) 155 (45.2) 21 (26.6)
Ever entered treatment for drug-related problems before (vs. Never before) 388 (67.7) 67 (62.6) 244 (69.9) 51 (63.8)
Never tested for HCV before (vs. Tested for HCV before) 182 (32.1) 56 (51.9) 109 (32.2) 10 (12.3)
Never tested for HIV before (vs. Tested for HIV before) 192 (30.7) 50 (45.9) 100 (29.2) 12 (14.8)
  1. aOST entrants with both statuses known, excluding four with HIV monoinfection. bDiagnosed HCV negative and HIV negative. cDiagnosed HCV positive and HIV negative. dDiagnosed HCV positive and HIV positive. eWhere applicable, Median [Interquartile means] or Mean [Standard deviation]. fGender was measured by the following item: “What is your gender?” Response options included “male”, “female”, “other (transgender)”. No person responded “other” in the sample used in the present analysis. gIncludes children and/or parents. hThe category “economically inactive” includes the long-term sick, unpaid carers and persons living on pensions or benefits, but excludes students. iTobacco use was not measured. Possible abuse of alcohol or non-medical use of prescription drugs is included